Welcome to the CCO Site

Thank you for your interest in CCO content. As a guest, please complete the following information fields. These data help ensure our continued delivery of impactful education. 

Become a member (or login)? Member benefits include accreditation certificates, downloadable slides, and decision support tools.

Submit

Digital Technologies in Diabetes Management: Considerations for Delivering State-of-the-Art Care

Credits Available
Pharmacists: 1.5 contact hours (0.15 CEUs)
Released: April 18, 2022 Expiration: April 17, 2023
Start Activity
Provided by ProCE, LLC.

Contact Clinical Care Options

For customer support please email: customersupport@cealliance.com

Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

Supported by an educational grant from
Abbott Diabetes Care Inc.
Medtronic
Andrew Bzowyckyi, PharmD, BCPS, CDCES
Diana Isaacs, PharmD, BCPS, BCACP, CDCES, BC-ADM, FADCES, FCCP

Learning Objectives

Upon completion of this activity, participants should be able to:
  • Evaluate new and emerging diabetes technologies, including their role in reducing A1C, hypoglycemia, and postprandial hyperglycemia and improving time in range
  • Identify methods to overcome potential barriers to incorporating CGM or insulin-delivery devices into the care of a patient with diabetes
  • Discuss the role of the pharmacist in utilization of diabetes technologies in practice, including patient engagement and education, shared decision-making, and counseling patients on how diabetes technology can improve adherence and glycemic outcomes

Information on this Educational Activity

ProCE, LLC requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose all financial conflicts of interest (COI) they may have with ineligible companies. All relevant COI are thoroughly vetted and mitigated according to ProCE policy. ProCE is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.

The faculty reported the following relevant financial relationships or relationships to products or devices they have with ineligible companies related to the content of this educational activity:

Faculty

Andrew Bzowyckyi, PharmD, BCPS, CDCES

Associate Professor
School of Pharmacy
Pacific University Oregon
Hillsboro, Oregon
Clinic Pharmacist
Legacy Medical Group Cornell
Beaverton, Oregon

Andrew Bzowyckyj, PharmD, BCPS, CDCES, has disclosed that he has received consultant/advisor/speaker fees from Sanofi.
Diana Isaacs, PharmD, BCPS, BCACP, CDCES, BC-ADM, FADCES, FCCP

Endocrine Clinical Pharmacy Specialist
CGM and Remote Monitoring Program Coordinator

Endocrinology and Metabolism Institute
Cleveland Clinic
Cleveland, Ohio

Diana Isaacs, PharmD, BCPS, BCACP, CDCES, BC-ADM, FADCES, FCCP, has disclosed that she has received consultant/advisor/speaker fees from Abbott, Dexcom, Insulet, Klinio, Medtronic, and Novo Nordisk.

Staff

ProCE staff and planners have no relevant conflicts of interest to report.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Target Audience

The target audience for this activity is pharmacists, including community, ambulatory care, primary care, and clinical pharmacists, who care for patients with diabetes who would benefit from diabetes technology and pharmacy directors, chief pharmacy officers, and other stakeholders in pharmacy practice.

Goal

The goal of this activity is to improve the knowledge and competence of pharmacists about how current and emerging digital technology within diabetes care can improve glycemic control and how to best implement its use in clinical practice.

Continuing Pharmacy Education

ProCE, LLC is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. ACPE Universal Activity Number 0221-0000-22-094-H01-P has been assigned to this home study, application-based activity. This activity is approved for 1.5 contact hours (0.15 CEU) in states that recognize ACPE providers. The activity is provided at no cost to participants. Completion of an evaluation and post-test with a score of 70% or higher is required to receive CE credit. Proof of completion will be posted in NABP CPE Monitor profiles. No partial credit will be given.

Program Medium

This program has been made available online.

Instructions for Credit

Participation in this self-study activity should be completed in approximately 1.5 hours. To successfully complete this activity and receive credit, participants must follow these steps during the period from April 18, 2022, through April 17, 2023:

1. Register online at http://www.clinicaloptions.com.
2. Read the target audience, learning objectives, and faculty disclosures.
3. Study the educational activity online or printed out.
4. Submit answers to the posttest questions and evaluation questions online.

You must receive a test score of at least 70% and respond to all evaluation questions to receive a certificate. After submitting the evaluation, you may access your online certificate by selecting the certificate link on the posttest confirmation page. Records of all CME/CE activities completed can be found on the "CME/CE Manager" page. There are no costs/fees for this activity.

Digital Technologies in Diabetes Management: Considerations for Delivering State-of-the-Art Care

Loading...
Interactive on demand webinar providing expert insights on strategies for successful implementation of digital technologies to improve outcomes in persons with diabetes.
Andrew Bzowyckyi, PharmD, BCPS, CDCES
Diana Isaacs, PharmD, BCPS, BCACP, CDCES, BC-ADM, FADCES, FCCP
Pharmacists: 1.5 contact hours (0.15 CEUs)
Released: April 18, 2022 Expiration: April 17, 2023

Related Content

Expert faculty insight on evidence for finerenone use in DKD, selecting patients for therapy, overcoming clinical inertia, from ProCE

Diana Isaacs, PharmD, BCPS, BCACP, CDCES, BC-ADM, FADCES, FCCP Joshua J. Neumiller, PharmD, CDCES, FADCES, FASCP Pharmacists: 1.5 contact hours (0.15 CEUs) Released: April 29, 2022 Expired: April 28, 2023

Concise microlearning module featuring patient educaiton video and expert insight on overcoming barriers for use of GLP-1 RAs for obesity from ProCE

Megan Adelman, PharmD, BCPS, BCGP, CDCES Elizabeth Pogge, PharmD, MPH, BCPS-AQ Cardiology, BCGP, FASCP, FAzPA Pharmacists: 0.25 contact hours (0.025 CEUs) Released: April 8, 2022 Expired: April 7, 2023

Concise microlearning module featuring patient education video and expert insight on dosing, titration, and administration of injectable medications for obesity, from ProCE

Megan Adelman, PharmD, BCPS, BCGP, CDCES Elizabeth Pogge, PharmD, MPH, BCPS-AQ Cardiology, BCGP, FASCP, FAzPA Pharmacists: 0.5 contact hours (0.05 CEUs) Released: April 8, 2022 Expired: April 7, 2023

Concise microlearning module featuring expert insight on obesity, including pathophysiology, common comorbidities, and benefits of long-term weight loss from ProCE

Megan Adelman, PharmD, BCPS, BCGP, CDCES Elizabeth Pogge, PharmD, MPH, BCPS-AQ Cardiology, BCGP, FASCP, FAzPA Pharmacists: 0.25 contact hours (0.025 CEUs) Released: April 8, 2022 Expired: April 7, 2023
Provided by ProCE, LLC.

Contact Clinical Care Options

For customer support please email: customersupport@cealliance.com

Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

Supported by an educational grant from
Abbott Diabetes Care Inc.
Medtronic

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue

Cookie Settings